ArticleInternal medicine (Tokyo, Japan)2026
Paraneoplastic Anti-N-methyl-D-aspartate Receptor Encephalitis Associated with Small Cell Lung Cancer: A Dramatic Recovery after Chemotherapy.
Article in Internal medicine (Tokyo, Japan), 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Tumor management is the cornerstone of treatment for anti-N-methyl-D-aspartate receptor (anti-NMDAR) encephalitis that is refractory to immunosuppressive therapy. However, little is known about the effectiveness of chemotherapy for malignant tumors in patients with severe neurological conditions. We herein report a 66-year-old male who fell into a coma caused by anti-NMDAR encephalitis associated with small cell lung cancer (SCLC). Corticosteroid pulse therapy failed to improve his neurological condition, but a chemotherapy regimen containing atezolizumab led to rapid improvement in his condition. This case suggests that chemotherapy, including atezolizumab, may provide a rapid therapeutic benefit for anti-NMDAR encephalitis associated with SCLC.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.